Skip to main content
. 2024 Apr 11;72:102592. doi: 10.1016/j.eclinm.2024.102592

Fig. 1.

Fig. 1

Progression-free survival of patients with marginal zone lymphoma according to MZL-IPI risk category (low, intermediate, high) (training sample) (A) and of patients from US Cohort (the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence, SPORE, Molecular Epidemiology Resource, MER, and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA) (validation sample) (B).